Treatment with bevacizumab plus carboplatin for recurrent malignant glioma

Eric M. Thompson, Edit Dosa, D. Kraemer, Edward A. Neuwelt

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

OBJECTIVE: To estimate overall survival (OS), progression-free survival (PFS), imaging responses, and toxicities of bevacizumab plus carboplatin for the treatment of recurrent malignant glioma. The secondary objective was to estimate the agreement between postcontrast T1-weighted and T2-weighted magnetic resonance imaging. METHODS: A retrospective analysis of 9 patients who received bevacizumab (10 mg/kg intravenously) and carboplatin (AUC 5 intravenously) for recurrent malignant glioma (World Health Organization grades III and IV) is presented. Eight of 9 patients received this regimen at first recurrence. RESULTS: The median age and Karnofsky performance score were 51 years and 70, respectively. For the 5 patients with grade III gliomas, the median PFS was 126 days, whereas median OS was not attained at 517 days of follow-up. Six-month PFS was 40%, whereas 6-month OS was 60%. For the 4 patients with grade IV gliomas, the median PFS was 216 days, whereas the median OS was not attained at 482 days of follow-up. Six-month PFS was 50%, whereas 6-month OS was 75%. The agreement between contrast-enhanced T1-weighted and T2-weighted images to determine recurrence was moderate (kappa = 0.5714). Three patients had grade 3 and 4 toxicities including hyponatremia and thrombocytopenia. CONCLUSION: Patients who reveived the combination of bevacizumab plus carboplatin for recurrent malignant glioma had reasonable PFS, OS, and toxicities. The median OS in our series is promising at well over 1 year. Agreement between postcontrast T1- and T2-weighted images is only moderate in the context of bevacizumab therapy.

Original languageEnglish
Pages (from-to)87-93
Number of pages7
JournalNeurosurgery
Volume67
Issue number1
DOIs
Publication statusPublished - Jul 2010

Fingerprint

Carboplatin
Glioma
Disease-Free Survival
Survival
Therapeutics
Recurrence
Hyponatremia
Bevacizumab
Thrombocytopenia
Area Under Curve
Magnetic Resonance Imaging

Keywords

  • Bevacizumab
  • Carboplatin
  • Imaging response
  • Recurrent malignant glioma
  • Toxicity

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. / Thompson, Eric M.; Dosa, Edit; Kraemer, D.; Neuwelt, Edward A.

In: Neurosurgery, Vol. 67, No. 1, 07.2010, p. 87-93.

Research output: Contribution to journalArticle

Thompson, Eric M. ; Dosa, Edit ; Kraemer, D. ; Neuwelt, Edward A. / Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. In: Neurosurgery. 2010 ; Vol. 67, No. 1. pp. 87-93.
@article{8fcc59e6509846dcaa64e371e40ce821,
title = "Treatment with bevacizumab plus carboplatin for recurrent malignant glioma",
abstract = "OBJECTIVE: To estimate overall survival (OS), progression-free survival (PFS), imaging responses, and toxicities of bevacizumab plus carboplatin for the treatment of recurrent malignant glioma. The secondary objective was to estimate the agreement between postcontrast T1-weighted and T2-weighted magnetic resonance imaging. METHODS: A retrospective analysis of 9 patients who received bevacizumab (10 mg/kg intravenously) and carboplatin (AUC 5 intravenously) for recurrent malignant glioma (World Health Organization grades III and IV) is presented. Eight of 9 patients received this regimen at first recurrence. RESULTS: The median age and Karnofsky performance score were 51 years and 70, respectively. For the 5 patients with grade III gliomas, the median PFS was 126 days, whereas median OS was not attained at 517 days of follow-up. Six-month PFS was 40{\%}, whereas 6-month OS was 60{\%}. For the 4 patients with grade IV gliomas, the median PFS was 216 days, whereas the median OS was not attained at 482 days of follow-up. Six-month PFS was 50{\%}, whereas 6-month OS was 75{\%}. The agreement between contrast-enhanced T1-weighted and T2-weighted images to determine recurrence was moderate (kappa = 0.5714). Three patients had grade 3 and 4 toxicities including hyponatremia and thrombocytopenia. CONCLUSION: Patients who reveived the combination of bevacizumab plus carboplatin for recurrent malignant glioma had reasonable PFS, OS, and toxicities. The median OS in our series is promising at well over 1 year. Agreement between postcontrast T1- and T2-weighted images is only moderate in the context of bevacizumab therapy.",
keywords = "Bevacizumab, Carboplatin, Imaging response, Recurrent malignant glioma, Toxicity",
author = "Thompson, {Eric M.} and Edit Dosa and D. Kraemer and Neuwelt, {Edward A.}",
year = "2010",
month = "7",
doi = "10.1227/01.NEU.0000370918.51053.BC",
language = "English",
volume = "67",
pages = "87--93",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Treatment with bevacizumab plus carboplatin for recurrent malignant glioma

AU - Thompson, Eric M.

AU - Dosa, Edit

AU - Kraemer, D.

AU - Neuwelt, Edward A.

PY - 2010/7

Y1 - 2010/7

N2 - OBJECTIVE: To estimate overall survival (OS), progression-free survival (PFS), imaging responses, and toxicities of bevacizumab plus carboplatin for the treatment of recurrent malignant glioma. The secondary objective was to estimate the agreement between postcontrast T1-weighted and T2-weighted magnetic resonance imaging. METHODS: A retrospective analysis of 9 patients who received bevacizumab (10 mg/kg intravenously) and carboplatin (AUC 5 intravenously) for recurrent malignant glioma (World Health Organization grades III and IV) is presented. Eight of 9 patients received this regimen at first recurrence. RESULTS: The median age and Karnofsky performance score were 51 years and 70, respectively. For the 5 patients with grade III gliomas, the median PFS was 126 days, whereas median OS was not attained at 517 days of follow-up. Six-month PFS was 40%, whereas 6-month OS was 60%. For the 4 patients with grade IV gliomas, the median PFS was 216 days, whereas the median OS was not attained at 482 days of follow-up. Six-month PFS was 50%, whereas 6-month OS was 75%. The agreement between contrast-enhanced T1-weighted and T2-weighted images to determine recurrence was moderate (kappa = 0.5714). Three patients had grade 3 and 4 toxicities including hyponatremia and thrombocytopenia. CONCLUSION: Patients who reveived the combination of bevacizumab plus carboplatin for recurrent malignant glioma had reasonable PFS, OS, and toxicities. The median OS in our series is promising at well over 1 year. Agreement between postcontrast T1- and T2-weighted images is only moderate in the context of bevacizumab therapy.

AB - OBJECTIVE: To estimate overall survival (OS), progression-free survival (PFS), imaging responses, and toxicities of bevacizumab plus carboplatin for the treatment of recurrent malignant glioma. The secondary objective was to estimate the agreement between postcontrast T1-weighted and T2-weighted magnetic resonance imaging. METHODS: A retrospective analysis of 9 patients who received bevacizumab (10 mg/kg intravenously) and carboplatin (AUC 5 intravenously) for recurrent malignant glioma (World Health Organization grades III and IV) is presented. Eight of 9 patients received this regimen at first recurrence. RESULTS: The median age and Karnofsky performance score were 51 years and 70, respectively. For the 5 patients with grade III gliomas, the median PFS was 126 days, whereas median OS was not attained at 517 days of follow-up. Six-month PFS was 40%, whereas 6-month OS was 60%. For the 4 patients with grade IV gliomas, the median PFS was 216 days, whereas the median OS was not attained at 482 days of follow-up. Six-month PFS was 50%, whereas 6-month OS was 75%. The agreement between contrast-enhanced T1-weighted and T2-weighted images to determine recurrence was moderate (kappa = 0.5714). Three patients had grade 3 and 4 toxicities including hyponatremia and thrombocytopenia. CONCLUSION: Patients who reveived the combination of bevacizumab plus carboplatin for recurrent malignant glioma had reasonable PFS, OS, and toxicities. The median OS in our series is promising at well over 1 year. Agreement between postcontrast T1- and T2-weighted images is only moderate in the context of bevacizumab therapy.

KW - Bevacizumab

KW - Carboplatin

KW - Imaging response

KW - Recurrent malignant glioma

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=77954129869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954129869&partnerID=8YFLogxK

U2 - 10.1227/01.NEU.0000370918.51053.BC

DO - 10.1227/01.NEU.0000370918.51053.BC

M3 - Article

C2 - 20559095

AN - SCOPUS:77954129869

VL - 67

SP - 87

EP - 93

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 1

ER -